Systematic Review: Impact of Interferon-based Therapy on HCV-related Hepatocellular Carcinoma

Overview

Journal Sci Rep

Specialty Science

Date 2015 May 13

PMID 25963067

Citations 27

Authors

Ching-Sheng Hsu

You-Chen Chao

Hans Hsienhong Lin

Ding-Shinn Chen

Jia-Horng Kao

Affiliations

Soon will be listed here.

Abstract

Hepatitis C virus (HCV) is the leading cause of hepatocellular carcinoma (HCC), and several antiviral agents are available for the treatment of chronic HCV infection. However, the impact of antiviral therapy on the long-term outcomes of HCV-related HCC patients remains inconclusive. We aimed to examine the impact of antiviral therapy on the long-term outcomes of HCV-related HCC patients. We conducted a systematic review using PRISMA guidelines to identify trials and English-language literature from PubMed, Ovid MEDLINE, Scopus and the Cochrane Library database till August 2014. Randomized trials of antiviral treatments examining the effects of antiviral therapy on CHC patients and HCV-related HCC patients were screened and selected. We identified 6 trials evaluated the effectiveness of interferon (IFN)-alfa treatment, 3 studies examined pegylated interferon-alfa treatment, and 2 studies examined IFN-beta treatment. IFN-based therapy may decrease HCC incidence in HCV cirrhotic patients after a >5-year follow-up, improve liver reserve, decrease HCC recurrence rate, and increase survival rate in HCV-related HCC patients after curative HCC therapy. In conclusion, IFN-based therapy is beneficial and may be recommended in the management of HCV-related HCC patients who are IFN eligible.

Citing Articles

Hepatitis C Virus (HCV) Infection: Pathogenesis, Oral Manifestations, and the Role of Direct-Acting Antiviral Therapy: A Narrative Review.

Di Stasio D, Guida A, Romano A, Petruzzi M, Marrone A, Fiori F J Clin Med. 2024; 13(14).

PMID: 39064052 PMC: 11278420. DOI: 10.3390/jcm13144012.

British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults.

Suddle A, Reeves H, Hubner R, Marshall A, Rowe I, Tiniakos D Gut. 2024; 73(8):1235-1268.

PMID: 38627031 PMC: 11287576. DOI: 10.1136/gutjnl-2023-331695.

Downregulated expression of PBRM1 in sarcomatoid hepatocellular carcinoma.

Yoshida T, Sakai K, Kaibori M, Ishida M, Tanaka S, Kubo S Oncol Lett. 2024; 27(3):124.

PMID: 38348389 PMC: 10859838. DOI: 10.3892/ol.2024.14257.

Assessing the impact of direct-acting antivirals on hepatitis C complications: a systematic review and meta-analysis.

Yew K, Tan Q, Lim P, Low W, Lee C Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(3):1421-1431.

PMID: 37728622 DOI: 10.1007/s00210-023-02716-x.

Effect of direct-acting antivirals for hepatitis C virus-related hepatocellular carcinoma recurrence and death after curative treatment.

Ahn Y, Lee H, Han J, Cho H, Cheong J, Park B J Liver Cancer. 2023; 22(2):125-135.

PMID: 37383412 PMC: 10035739. DOI: 10.17998/jlc.2022.05.24.

References

Bernardinello E, Cavalletto L, Chemello L, Mezzocolli I, Donada C, Benvegnu L . Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology. 2000; 46(30):3216-22. View

Kusano H, Akiba J, Ogasawara S, Sanada S, Yasumoto M, Nakayama M . Pegylated interferon-α2a inhibits proliferation of human liver cancer cells in vitro and in vivo. PLoS One. 2013; 8(12):e83195. PMC: 3861497. DOI: 10.1371/journal.pone.0083195. View

Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F . Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000; 32(2):228-32. DOI: 10.1053/jhep.2000.9409. View

Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O . Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med. 2001; 134(10):963-7. DOI: 10.7326/0003-4819-134-10-200105150-00010. View

Vale C, Tierney J, Stewart L . Effects of adjusting for censoring on meta-analyses of time-to-event outcomes. Int J Epidemiol. 2002; 31(1):107-11. DOI: 10.1093/ije/31.1.107. View

Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H . Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg. 2002; 89(4):418-22. DOI: 10.1046/j.0007-1323.2001.02054.x. View

Miyaguchi S, Watanabe T, Takahashi H, Nakamura M, Saito H, Ishii H . Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepatogastroenterology. 2002; 49(45):724-9. View

Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S . Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003; 138(4):299-306. DOI: 10.7326/0003-4819-138-4-200302180-00008. View

Easterbrook P, Berlin J, Gopalan R, Matthews D . Publication bias in clinical research. Lancet. 1991; 337(8746):867-72. DOI: 10.1016/0140-6736(91)90201-y. View

10.

Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S . Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995; 346(8982):1051-5. DOI: 10.1016/s0140-6736(95)91739-x. View

11.

Chen D . Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp. 1995; 25:27-32. View

12.

Yano H, Iemura A, Haramaki M, Ogasawara S, Takayama A, Akiba J . Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology. 1999; 29(6):1708-17. DOI: 10.1002/hep.510290624. View

13.

Valla D, Chevallier M, Marcellin P, Payen J, Trepo C, Fonck M . Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology. 1999; 29(6):1870-5. DOI: 10.1002/hep.510290616. View

14.

Nishiguchi S, Tamori A, Kubo S . Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology. 2005; 48(1):71-5. DOI: 10.1159/000082098. View

15.

Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S . Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006; 44(6):1543-54. DOI: 10.1002/hep.21415. View

16.

Wright R, Brand R, Dunn W, Spindler K . How to write a systematic review. Clin Orthop Relat Res. 2007; 455:23-9. DOI: 10.1097/BLO.0b013e31802c9098. View

17.

Di Bisceglie A, Shiffman M, Everson G, Lindsay K, Everhart J, Wright E . Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008; 359(23):2429-41. PMC: 2606037. DOI: 10.1056/NEJMoa0707615. View

18.

Ghany M, Strader D, Thomas D, Seeff L . Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4):1335-74. PMC: 7477893. DOI: 10.1002/hep.22759. View

19.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

20.

Lok A, Everhart J, Wright E, Di Bisceglie A, Kim H, Sterling R . Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2010; 140(3):840-9. PMC: 3057272. DOI: 10.1053/j.gastro.2010.11.050. View